Plain-English translation of NCT06432582 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is evaluating hepatomiR, a blood test that's already approved for medical use, to see if it can predict when people with advanced chronic liver disease might develop serious complications like fluid buildup in the belly, internal bleeding, or confusion. Researchers want to understand what causes these complications and use this information to help doctors better manage and treat the disease in the future.
Currently, doctors struggle to predict when people with advanced liver disease will develop serious complications. By identifying a blood marker that can forecast these events, this research could help doctors catch problems earlier and adjust treatment plans before complications occur.
You likely qualify if…
You likely don't qualify if…
As a participant, you would visit the hospital clinic as an outpatient and have blood drawn for the hepatomiR test. The study collects this blood sample data along with information about your liver disease to identify patterns that predict complications. There is no medication to take or invasive procedures — it's primarily a blood test and data collection study to help researchers understand your condition better.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Austria
Collaborators
University Hospital St. Polten
Enrollment target
~156 participants
Started
May 2024
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lukas Erhart, Mag. Dr.
Karl Landsteiner University of Health Sciences
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.